What the Recent FDA Peptide News Actually Means

In July, the FDA’s Pharmacy Compounding Advisory Committee met to review several peptide-related bulk drug substances being considered for inclusion on what’s known as the 503A Bulks List. Among the substances discussed were BPC-157, KPV, TB-500, MOTS-C, Semax, Epitalon and others. It’s an important regulatory conversation, but there’s an equally important distinction:
An FDA advisory committee reviewing a peptide is not the same thing as the FDA approving that peptide as a drug. The committee’s job is to examine the available scientific evidence and make recommendations to the FDA. Those recommendations are advisory and non-binding.

What I appreciate about the recent discussion is that peptides are being evaluated through the lens they deserve: science, safety, evidence and appropriate medical use. There is exciting research surrounding peptide therapies, but there are also unanswered questions. For several compounded peptides, the FDA has specifically noted that human safety data remain limited. That’s something patients deserve to know. At Ageless Units, I don’t believe responsible medicine means jumping on every new wellness trend. It means looking at the evidence, understanding what we know and what we don’t know, evaluating each patient individually, and continuing to follow the science as it evolves.

Another important part of this conversation is where your medication comes from. Peptides purchased online or through questionable sources are not the same thing as medication obtained through an appropriately licensed pharmacy. Quality, sterility, potency, ingredient verification and proper handling matter—especially with compounded medications. At Ageless Units, when compounded therapies are prescribed, we work with licensed compounding pharmacy partners and take sourcing seriously. But it’s also important to understand that compounded medications are not FDA-approved drugs. They don’t go through the same FDA premarket review for safety, effectiveness and manufacturing quality as an FDA-approved medication. That’s one of the reasons medical oversight and responsible sourcing are so important.

Curious. And that’s perfectly reasonable.

There is promising research happening in peptide medicine, and this is an area we’re going to continue watching closely. But peptide therapy shouldn’t begin with:
“I saw this on TikTok. Can I get it?”

It should begin with a conversation. What are you trying to improve? What symptoms are you experiencing? What does your medical history look like? What medications are you currently taking?What does the evidence tell us about the therapy you’re considering? And does the potential benefit make sense for you?

Those are the conversations I want to have with my patients.

Healthcare is constantly evolving. New research emerges. Regulations change. Treatments improve. Sometimes new evidence causes us to rethink what we’ve done before. That’s a good thing. My responsibility as a provider isn’t to chase every new treatment—or dismiss something simply because it’s new. It’s to continue learning, ask questions, follow the evidence and help my patients make informed decisions about their health. If you’ve been hearing about peptide therapy and wondering whether it might have a place in your health or wellness plan, schedule a consultation. We’ll talk about your goals, your health and the options that may—or may not—make sense for you.

Education first. Treatment second. Always.